Research programme: DNA vaccines - Admedus Immunotherapies

Drug Profile

Research programme: DNA vaccines - Admedus Immunotherapies

Alternative Names: AMV 002; EBV vaccine - Admedus Immunotherapies; Epstein Barr Virus vaccine - Admedus Immunotherapies; HPV vaccine - Admedus Immunotherapies; Human papillomavirus vaccine - Admedus Immunotherapies

Latest Information Update: 16 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Queensland
  • Developer Admedus Immunotherapies
  • Class Cancer vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human papillomavirus infections
  • Research Epstein-Barr virus infections; Lymphoma
  • No development reported Cervical cancer

Most Recent Events

  • 16 Feb 2018 Admedus Vaccines is now called Admedus Immunotherapies
  • 09 Feb 2018 Preclinical development is ongoing for Human papillomavirus infections in Australia (ACTRN12618000140257)
  • 09 Feb 2018 Admedus plans a phase I trial of AMV 002 for Human papillomavirus infections-associated Head and neck cancer in Australia (ACTRN12618000140257)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top